Len-604
Len-604 is a FGFR inhibitor with IC50 values of 9.71 nM, 9.93 nM, 29.80 nM and 14.48 nM against FGFR4, FGFR1, FGFR2 and FGFR3, respectively. Len-604 reduces the phosphorylation levels of FGFR4 and ERK, and induces DNA damage and apoptosis in cancer cells. Len-604 is applicable to research related to liver cancer.
For research use only. We do not sell to patients.
- Formula: C30H33ClN8O9Pt
- Molecular Weight:880.17
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
ERK1 |
ERK2 |
In Vitro
Len-604 (72 h) exhibits potent cytotoxicity against HUH-7 and SMMC-7721 human hepatocellular carcinoma cells (IC50 = 5.62 μM and 5.64 μM, respectively), and shows high selectivity toward non-cancerous L02 hepatocytes[1].
Len-604 (10-30 μM; 24 h) induces dose-dependent apoptosis in human hepatocellular carcinoma HUH-7 cells, with the apoptosis rate reaching 51.1% after treatment with 30 μM for 24 h[1].
Len-604 (10 μM; 24 h) induces S-phase cell cycle arrest in human hepatocellular carcinoma cell line HUH-7 after 24 h of incubation[1].
Len-604 (10-20 μM; 24 h) downregulates the levels of p-FGFR4 and p-ERK1/2 in human hepatocellular carcinoma cell line HUH-7 in a dose-dependent manner, without altering the protein levels of total FGFR4 and ERK1/2[1].
Len-604 (10 μM; 12-24 h) induces significant DNA damage in human hepatocellular carcinoma cell line HUH-7, as evidenced by elevated γ-H2AX expression levels and DNA strand breaks detected via the comet assay[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HUH-7
-
Concentration:10, 20 and 30 μM
-
Incubation Time:24 h
-
Result:Induced cell apoptosis in a dose-dependent manner.
At 10 μM, showed an apoptotic ratio higher than lenvatinib but lower than cisplatin and the lenvatinib-cisplatin mixture.
At 30 μM, reached an apoptotic ratio of 51.1%.
-
Cell Line:HUH-7
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Decreased G0-G1 phase cell distribution from 77.7% to 67.5% compared to control.
Increased S-phase distribution from 15.7% to 30.7% compared to control.
Caused S-phase arrest similar to cisplatin and the lenvatinib-cisplatin mixture.
-
Cell Line:HUH-7
-
Concentration:10 and 20 μM
-
Incubation Time:24 h
-
Result:Downregulated phosphorylated FGFR4 (p-FGFR4) in a dose-dependent manner.
Downregulated phosphorylated ERK1/2 (p-ERK1/2) in a dose-dependent manner.
Left levels of total FGFR4 and ERK1/2 unchanged.
At 10 μM, showed inhibition of p-FGFR4 nearly equivalent to lenvatinib.
In Vivo
Len-604 (15-25 mg/kg; i.v.; once weekly; 21 days) achieves 64.96% and 91.98% tumor growth inhibition, respectively, in HUH-7 xenograft mice with low systemic toxicity and dose-dependent suppression of FGFR4/ERK signaling[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 6 weeks old, 16−18 g, HUH-7 hepatocellular carcinoma xenograft)[1]
-
Dosage:5.0 mg/kg
-
Administration:i.v.; once weekly; 14 days
-
Result:Achieved a tumor growth inhibition (TGI) rate of 61.25%.
Showed no significant mouse weight loss, indicating low systemic toxicity.
-
Animal Model:BALB/c nude (female, 6 weeks old, 16−18 g, HUH-7 hepatocellular carcinoma xenograft)[1]
-
Dosage:15.0 mg/kg; 25.0 mg/kg
-
Administration:i.v.; once weekly; 21 days
-
Result:Achieved a tumor growth inhibition (TGI) rate of 64.96% at 15.0 mg/kg.
Achieved a tumor growth inhibition (TGI) rate of 91.98% at 25.0 mg/kg.
Showed no significant changes in mouse body weight at both doses.
Revealed no toxic impacts on major organs (heart, liver, spleen, lung, kidney) via histopathological analysis.
Showed severe tumor cell degeneration/necrosis in tumor tissue sections.
Induced dose-dependent downregulation of phosphorylated FGFR4 (p-FGFR4) and phosphorylated ERK1/2 (p-ERK1/2) levels in tumor tissues via Western blot analysis.
Chemical Information
-
Molecular Weight 880.17
-
Formula C30H33ClN8O9Pt
-
SMILES
O=C(NC1CC1)NC2=C(Cl)C=C(OC3=CC=NC4=C3C=C(C(NCCC(N/N=C5CC6(C([O-][Pt+2]([NH3])([NH3])[O-]C6=O)=O)C\5)=O)=O)C(OC)=C4)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)